PERRY MATTHEW D 4
4 · CTI BIOPHARMA CORP · Filed May 20, 2019
Insider Transaction Report
Form 4
PERRY MATTHEW D
DirectorOther
Transactions
- Award
Non-Qualified Stock Option (Right to Buy)
2019-05-16+120,000→ 120,000 totalExercise: $0.84Exp: 2029-05-16→ Common Stock (120,000 underlying)
Holdings
- 60,000
Non-Qualified Stock Option (Right to Buy)
Exercise: $4.61Exp: 2028-05-17→ Common Stock (60,000 underlying) - 50,000
Stock Option (Right to Buy)
Exercise: $4.25Exp: 2027-02-22→ Common Stock (50,000 underlying) - 43,139
Common Stock
Footnotes (4)
- [F1]The Reporting Person may be deemed to be a member of a Section 13(d) group that may be deemed to collectively beneficially own more than 10% of the Issuer's outstanding shares of Common Stock.
- [F2]The option will vest on the first to occur of (i) the date that is twelve months after the date of grant, and (ii) immediately prior to the first annual meeting of the Company's stockholders in 2020 at which one or more members of the Company's Board of Directors are to be elected, subject to the Reporting Person's continued service through such date or event.
- [F3]This stock option was granted on May 17, 2018 and vested on the first to occur of (i) the date that was twelve months after the date of grant, and (ii) immediately prior to the first annual meeting of the Company's stockholders in 2019 at which one or more members of the Company's Board of Directors are to be elected, subject to the Reporting Person's continued service through such date or event.
- [F4]This stock option was granted on February 23, 2017, and vested on the first to occur of (i) the date that was twelve months after the date of grant, (ii) the first annual meeting of CTIC's shareholders in 2018 at which one or more members of the CTIC Board of Directors was elected, or (iii) immediately prior to the occurrence of a Change of Control (as such term is defined in CTIC's 2015 Equity Incentive Plan).